Guangdong Biolight Meditech Co Ltd (300246) — Strategic Asset Allocation Index
Guangdong Biolight Meditech Co Ltd (300246) has a Strategic Asset Allocation Index of 49.6% as of March 2023. Strategic assets (PP&E of CN¥761.97 Million plus long-term investments of CN¥-) total CN¥761.97 Million, measured against net assets of CN¥1.54 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Guangdong Biolight Meditech Co Ltd Strategic Asset Allocation Index (2008–2022)
This chart shows how Guangdong Biolight Meditech Co Ltd's Strategic Asset Allocation Index has evolved across 15 annual periods from 2008 to 2022. As of March 2023, the index stands at 49.6%, representing strategic assets of CN¥761.97 Million against net assets of CN¥1.54 Billion CNY. Explore Guangdong Biolight Meditech Co Ltd operating cash flow efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Guangdong Biolight Meditech Co Ltd (2008–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Guangdong Biolight Meditech Co Ltd from 2008 to 2022, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Guangdong Biolight Meditech Co Ltd market cap and net worth.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 49.1% | CN¥737.85 Million | CN¥737.85 Million | CN¥- | CN¥1.50 Billion | ▼ -9.8 pp |
| 2021 | 58.9% | CN¥584.72 Million | CN¥584.72 Million | CN¥- | CN¥992.38 Million | ▲ +16.1 pp |
| 2020 | 42.8% | CN¥442.18 Million | CN¥442.18 Million | CN¥- | CN¥1.03 Billion | ▲ +3.5 pp |
| 2019 | 39.3% | CN¥230.10 Million | CN¥230.10 Million | CN¥- | CN¥585.84 Million | ▲ +6.0 pp |
| 2018 | 33.3% | CN¥206.88 Million | CN¥204.78 Million | CN¥2.10 Million | CN¥622.19 Million | ▲ +5.1 pp |
| 2017 | 28.1% | CN¥155.78 Million | CN¥153.66 Million | CN¥2.12 Million | CN¥554.08 Million | ▲ +5.0 pp |
| 2016 | 23.1% | CN¥116.44 Million | CN¥114.44 Million | CN¥2.00 Million | CN¥504.27 Million | ▲ +3.3 pp |
| 2015 | 19.8% | CN¥91.40 Million | CN¥91.40 Million | CN¥- | CN¥460.87 Million | ▲ +0.3 pp |
| 2014 | 19.6% | CN¥83.74 Million | CN¥83.74 Million | CN¥- | CN¥427.94 Million | ▼ -3.0 pp |
| 2013 | 22.5% | CN¥88.82 Million | CN¥88.82 Million | CN¥- | CN¥393.88 Million | ▲ +10.2 pp |
| 2012 | 12.4% | CN¥46.75 Million | CN¥46.75 Million | CN¥- | CN¥377.93 Million | ▲ +5.0 pp |
| 2011 | 7.3% | CN¥26.00 Million | CN¥26.00 Million | CN¥- | CN¥354.32 Million | ▼ -13.1 pp |
| 2010 | 20.5% | CN¥18.40 Million | CN¥18.40 Million | CN¥- | CN¥89.93 Million | ▼ -2.8 pp |
| 2009 | 23.3% | CN¥15.59 Million | CN¥15.59 Million | CN¥- | CN¥66.94 Million | ▼ -6.0 pp |
| 2008 | 29.3% | CN¥13.62 Million | CN¥13.62 Million | CN¥- | CN¥46.53 Million | — |